Leadership

François Blondel
Chairman of the Board
Mr François Blondel is the Chairman of the Board of Directors and Managing Director of the company.

Having graduated in both Law and Science Economics, he nowadays combines executive functions (as CEO of KitoZyme) with non-executive board memberships, either as Chairman of the Board or as an independent Board member. The companies in which he is - or has been - active range from SME’s, spin-offs and Research centers, such as OncoDNA, NANOCYL (a world leader in production of carbon nanotubes), Delphi Genetics, KiOmed Pharma, etc. which are active in the technology, medical or healthcare sectors to major listed companies, such as RECTICEL (industrial multinational group - Euronext) or Compagnie du BOIS SAUVAGE (diversified holding – Euronext) and public authorities, such as AWEX (export agency for the Walloon Region), AMONIS (largest pension fund for MD's in Belgium) and BioWIN. As an entrepreneur, he has (co)founded several start-ups and gained broad experience in the management of innovation driven companies. He started his career in the chemical sector and undertook assignments both in the United States and in Europe. In 1999, he joined International Brachytherapy (IBt), a medical device startup that focused on cancer treatment. He served as CEO, leading IBt, a Euronext stock listed company, from its R&D stage to a successful and well-diversified international group that became a European leader in its market segment.

Cédric Szpirer
Executive & Scientific Director
Cédric Szpirer is Engineer in agronomy and obtained his PhD in molecular biology from Université Libre de Bruxelles in 2000. He founded Delphi Genetics in 2001 with two colleagues when he was Research associate at University of Brussels (laboratory of genetic evolution). He joined the company as first employee in 2004. He was firstly Head of research & development and in 2010, he combined this position with the executive direction of the company. He is now Executive & Scientific director of Delphi Genetics. He is also member of the board of Immunehealth. He is inventor or co-inventor of more than 10 patents families (issued and pending) in the field of molecular biology and more precisely in recombinant productions and DNA engineering. He was also involved in patent licensing & acquisition.

 

 

Marc Dechamps
Managing Director
Marc Dechamps is a biologist with an extensive experience in the Pharmaceutical industry in international and local business positions. He started his career by holding several sales and marketing positions  mainly at Glaxo, GlaxoWellcome and GSK. His last position at GSK Pharmaceuticals Belgium was Executive Director of the commercial departement « Specialty care & Vaccines ». End 2009 he became Head of the European Mid-Size Countries Region at ViiVHealthcare, a spin out company created by GSK and Pfizer in 2009. In paralell he built a European commercial operations team for the launch of the new assets of ViiVHealthcare. Before joining Delphi Genetics he was in charge of the European operations in Market Access / Pricing / Policies  and Commercial excellence of ViiVHealthcare.

Sophie Scohy
Services Director
After a PhD in molecular biology at Université Libre de Bruxelles and a post-doc at Institut Jules Bordet, Sophie Scohy joined Biovallée in 2001 as Research manager to set-up and manage the genetic engineering department. Sophie joined Delphi Genetics in 2005 to manage the genetic engineering services of the company. Since 2012,  she has been Services Director and manages now the service activity of the company.

 

Thierry Van Reeth
Scientific & Sales Manager
After a PhD in molecular Biology, he joined Biovallée in 2002 to set-up and manage the transgenic platform. From this activity, he founded BV transgenic Services where he was in charge of the management and the scientific activity until 2010. During the next 3 years, he was in charge of business development in the scientific recrutment field. He joined then Delphi Genetics in 2013 as Scientific and Sales Manager to develop and promote the service activity of the comapny.